WO2012138076A2 - Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales - Google Patents

Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales Download PDF

Info

Publication number
WO2012138076A2
WO2012138076A2 PCT/KR2012/002281 KR2012002281W WO2012138076A2 WO 2012138076 A2 WO2012138076 A2 WO 2012138076A2 KR 2012002281 W KR2012002281 W KR 2012002281W WO 2012138076 A2 WO2012138076 A2 WO 2012138076A2
Authority
WO
WIPO (PCT)
Prior art keywords
forget
prevention
gastrointestinal diseases
gastric
north sea
Prior art date
Application number
PCT/KR2012/002281
Other languages
English (en)
Korean (ko)
Other versions
WO2012138076A3 (fr
Inventor
정필구
Original Assignee
Jeong Pil Gu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110030581A external-priority patent/KR20110056459A/ko
Application filed by Jeong Pil Gu filed Critical Jeong Pil Gu
Publication of WO2012138076A2 publication Critical patent/WO2012138076A2/fr
Publication of WO2012138076A3 publication Critical patent/WO2012138076A3/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to a composition for the prevention or treatment of gastrointestinal diseases, comprising a mixed extract of forget-me-not and North Sea lake as an active ingredient.
  • the stomach is a long-term organ that stores food from the esophagus and breaks it down easily for digestion, and regulates the sending of food to the duodenum in harmony with the secretion of pancreatic enzymes for efficient digestion and absorption.
  • the stomach secretes gastric acid, a strong acid, to digest food when it comes in.
  • the mucosal protective layer acts to prevent damage to the gastric mucosa by gastric acid.
  • gastrointestinal disorders Factors that adversely affect the functioning of the gastrointestinal system of humans are extremely diverse. Such disorders can occur in the upper gastrointestinal tract, lower gastrointestinal tract, or both, and there are a wide range of gastrointestinal disorders, including genetic, physiological, environmental, and mental factors.
  • Chronic diseases of the upper gastrointestinal tract include gastritis and gastric ulcers, and inflammation occurs when gastric acid secretion is increased or gastric mucosal protective layer is damaged by various causes.
  • gastric ulcers Ulcers in the duodenum are also called duodenal ulcers, and stomach and duodenal ulcers are collectively called peptic ulcers.
  • abdominal pain which is the upper part of the abdomen, the heart and the right upper abdomen.
  • gastrointestinal diseases are diverse, largely due to the imbalance of physical and chemical attackers that cause damage to the gastric mucosa and in vivo defenses that act to defend the gastric mucosa from them and maintain homeostasis of gastric function.
  • Representative attackers include stress, alcohol, gastric acid, tobacco, painkillers such as aspirin, steroid preparations, irritating foods, malnutrition, and infection with Helicobacter pylori, and defense mechanisms include reactive oxygen species, It is closely related to the etiology of weakening antioxidant capacity against increase of ROS), mucus protecting gastric mucosa, decreased production of prostaglandin and reduced tissue regeneration and blood circulation.
  • the gastric mucosa when the gastric mucosa is damaged, inflammation, accompanied by erosion, redness, bleeding, and edema occurs, and when the damage is severe and penetrates the gastric mucosa, and the damage is extended to the lower mucosa and the muscle layer, the gastric ulcer develops.
  • the duodenal mucosa is damaged and dug deeper than the mucosal layer on the surface, and the duodenal ulcer occurs when the damage progresses beyond the mucosal muscle layer.
  • Nonsteroidal anti-inflammatory agents such as aspirin
  • gastric ulcers, gastritis and gastric bleeding by continuously applying oxidative stress to the gastric mucosa or forming oxidative radicals by metabolism in vivo.
  • antioxidant enzymes in gastric epithelial cells inhibit alcohol-induced damage to mucosal cells (Hiraishi et al., 1991). Hiraishi et al., 1999).
  • Prostaglandins which make up the gastric mucosal tissue, are synthesized by the COX (cyclooxygenase) enzyme factor, which plays a role in maintaining gastrointestinal homeostasis by inhibiting gastric acid secretion and promoting gastric mucus secretion and gastric mucosal cell growth.
  • COX cyclooxygenase
  • representative gastritis and gastric ulcer therapeutic agents include H2 antagonists and proton pump inhibitors, which have an effect of inhibiting gastric acid secretion, and these have proven excellent anti-ulcer effects in clinical practice.
  • these fast-acting gastric acid secretion inhibitors have a high recurrence rate after the end of the administration (Drug Intell Clin Pharm 21: 493, 1987, Gut 30: 449, 1989 Yale J Biol Med 65: 649, 1992)
  • Side effects such as diarrhea, metabolic alkalosis, and urolithiasis have been reported.
  • mucosal protective agents which have the effect of normalizing mucosal tissue function and promoting regeneration to resist re-attack of gastritis-inducing factors, are an important part of the treatment of gastritis.
  • Such protection of the gastric mucosa can be achieved through the strengthening of protective factors such as improved resistance to ischemic stress in the gastrointestinal tract and increased prostaglandin production as mentioned above.
  • drugs such as rebamipide and sofalcone have been developed and used as gastric mucosa protective agents, but generally, there is a short-acting effect, a high dose, and a relatively long-term need for improved drug development. .
  • the forget-me-not is the scientific name " Erigeron Canadensis.L” and is a perennial herb of the Asteraceae family, also called a small flower. Flowers bloom in July-September, and the leaves and stems are used for medicinal or edible foods.
  • all the leaves collected before flowering can be used.
  • Forget-me-not including leaves and stems
  • Forget-me-not including leaves and stems
  • outposts (flowers) cannot be used because they cause allergic respiratory diseases. .
  • North Sea Lake is the scientific name “ Buppleurum chinense DC ” and is a perennial herbaceous plant of the Apiaceae family.
  • the roots of the North Sea contain saponin and fatty oil, so they are used as herbal medicine. The effect is somewhat different depending on the place of origin, which is thought to be due to the growing environment of herbal medicines such as soil and climate.
  • the forget-me-not and the North Sea lake are widely used as herbal medicines in herbal medicine, but the prevention or treatment effect of gastrointestinal diseases such as gastritis and peptic ulcer of the mixed herbal medicine of the forget-me-not and North Sea lake is not known yet. There is no research on this.
  • the present inventors can use for a long time because there is no side effect in vivo, and as a result of continuing research to find a new herbal medicine that has the effect of preventing or treating gastrointestinal diseases, the mixed extract of forget-me-not and Hoshiho lake protects the gastric mucosa and stomach The present invention was completed by confirming that the ulcer inhibiting effect is excellent.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of gastrointestinal diseases, including a mixed extract of forget-me-not and North Sea Lake as an active ingredient.
  • Still another object of the present invention is to provide a food composition for preventing or improving gastrointestinal diseases, including a mixed extract of forget-me-not and Hoshiho lake as an active ingredient.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of gastrointestinal diseases comprising a mixed extract of forget-me-not and North Sea as an active ingredient.
  • the present invention provides a food composition for the prevention or improvement of gastrointestinal diseases comprising a mixed extract of forget-me-not and North Lake as an active ingredient.
  • Mixed extract of the forget-me-not and North Sea lake according to the present invention is excellent in the protective effect and gastric ulcer suppression effect of the gastric mucosa, it can be usefully used for the prevention or treatment of gastrointestinal diseases.
  • 1 is a diagram comparing the forget-me-not and forget-me-not of the present invention (left: forget-me-not, right: forget-me-not).
  • Figure 2 is a diagram showing the cytotoxicity of the mixed extract of the forget-me-not and North Sea lake of the present invention.
  • Figure 3 is a diagram showing the DPPH scavenging ability of the mixed extract of the forget-me-not and North Lake of the present invention.
  • 4 and 5 are diagrams showing the inhibitory activity of ROS generation in cells of the mixed extract of the forget-me-not and Hoshiho of the present invention.
  • Figure 6 is a diagram showing the effect of the mixed extract of the forget-me-not and North Lake of the present invention on IL-6 production.
  • Figure 7 is a diagram showing the effect of the mixed extract of the forget-me-not and North Sea lake of the present invention on the production of MCP-1.
  • TNF-alpha TNF- ⁇
  • Figure 9 is a diagram showing the stomach of the mouse used in the animal experiments to determine the gastrointestinal disease therapeutic effect of the mixed extract of the forget-me-not and North Sea lake of the present invention.
  • Figure 10 is a diagram showing the H & E staining of the stomach of the mouse in the animal experiment to confirm the gastrointestinal disease treatment effect of the mixed extract of the forget-me-not and North Sea lake of the present invention.
  • the present invention provides a composition for the prevention or treatment of gastrointestinal diseases, including a mixed extract of forget-me-not and North Sea lake as an active ingredient.
  • the composition may be provided in the form of a pharmaceutical composition or a food composition.
  • the mixed extract of the forget-me-not and the North Sea lake of the present invention can be obtained as follows.
  • the forget-me-not and the North Lake are washed with water to remove foreign substances, then dried in the shade and crushed.
  • the forget-me-not and the North Sea lake can be cultivated or commercially available without limitation.
  • an appropriate amount of solvent is added so as to be completely immersed.
  • the mixed powder of forget-me-not and North Lake is extracted using a solvent selected from water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, preferably extracted with ethanol.
  • the extraction can be impregnated or warmed at room temperature.
  • the extract is filtered and concentrated to give the final extract.
  • the forget-me-not and North Sea lake is preferably mixed with 5 to 15 parts by weight of the North Sea lake with respect to 100 parts by weight of forget-me-not.
  • the mixing ratio When it is out of the range of the mixing ratio, there is no significant difference in terms of the treatment effect of gastrointestinal diseases when compared to the case of using only the forget-me-not or Hoshiho extract alone, the drug efficacy is lowered, there is a fear of side effects.
  • Erigeron Canadensis.L is a different species from Erigeron annuus (L.) PERS.
  • L. Erigeron annuus
  • the north lake ( Bupleurum chinense DC ) means a Chinese lake , and is a species different from the domestic lake ( Bupleurum falcatum L. ). If Shiho is used instead of the North Sea, the treatment effect of gastrointestinal diseases is low and not suitable.
  • gastrointestinal disease is used herein in a broad sense, including all diseases and conditions that are associated with, or are likely to cause, damage to the gastric mucosa, regardless of their cause and mechanism.
  • the gastrointestinal diseases include acute gastritis, chronic active gastritis, chronic gastritis such as chronic atrophic gastritis, duodenitis, gastric ulcer, duodenal ulcer, gastric perforation, gastric bleeding, digestive disorders associated with nonsteroidal anti-inflammatory drugs (NSAIDs), non-ulcers sexual dyspepsia, gastroesophageal reflux disease (Reflux esophagitis), acute upper gastrointestinal bleeding, stress ulceration, Helicobacter pylori infection, Zolinger-Ellison syndrome (ZES), Werner's syndrome, and systemic obesity Symptoms such as but not limited to cytopathy and erosion, bleeding, redness and edema of the gastric mucosa due to the diseases.
  • Efficacy of the composition comprising a mixed extract of the forget-me-not and North Sea lake of the present invention is based on the protective effect of the gastric mucosa, and is not limited to gastrointestinal diseases due to specific causes or mechanisms. Accordingly, the disease can be caused by a variety of causes and mechanisms, including, for example, infections of alcohol, physical and mental stress, oxidative stress, gastric acid, nonsteroidal anti-inflammatory drugs, steroid preparations, tobacco, irritating foods, Helicobacter pylori. It may be caused by.
  • composition of the present invention may be used alone or in the form of a combination or aggregate with other pharmaceutically active compounds.
  • the active ingredients of the composition of the present invention can be administered in the form of a combination formulation mixed with other useful gastrointestinal diseases treatment drugs.
  • composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention or treatment of gastrointestinal diseases.
  • composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
  • suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions may be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., according to conventional methods, respectively.
  • Suitable formulations known in the art are preferably those disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA.
  • Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations are prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc., in the extract. It is prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the term "administration" means providing a subject with any of the compositions of the present invention in any suitable manner.
  • composition of the present invention can be administered to a subject by various routes. All modes of administration can be expected, for example by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
  • compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the like, but may be appropriately selected by those skilled in the art. However, for the desired effect, for adults, the compositions of the present invention may comprise from 1 to 1000 mg / kg body weight in a single dose. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • health functional food refers to a food prepared and processed using raw materials or ingredients having functional properties useful for the human body
  • functionality refers to nutrients or physiological effects on the structure and function of the human body. It means to consume for the purpose of obtaining a useful effect for health use such as.
  • the composition of the present invention When the composition of the present invention is used as a food composition, the composition may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
  • the compositions of the present invention are added in an amount of up to 15% by weight, preferably up to 10% by weight relative to the raw materials.
  • the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
  • the food composition of the present invention may be formulated in the formulation of conventional health functional foods known in the art.
  • the health functional food composition may be prepared, for example, as a powder, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, extracts, teas, jelly, or beverages.
  • any carrier or additive known to be usable in the art may be used to prepare a formulation to be prepared.
  • the sculptural extract of the present invention has various nutrients, vitamins, minerals (electrolytes), colorants and enhancers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like.
  • the health functional beverage composition of the present invention is not particularly limited in addition to the mixed extract of the forget-me-not and Hoshiho as essential components, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like; Sugar alcohols such as xylitol, sorbitol, erythritol and the like.
  • As the flavoring agent natural flavoring agents such as taumarin, stevia extract (rebaudioside A, glycyrzin, etc.); And synthetic flavoring agents such as saccharin, aspartame and the like.
  • the mixed extract of the forget-me-not and the North Sea lake of the present invention has a DPPH scavenging activity in proportion to the concentration, it was confirmed that the excellent antioxidant efficacy.
  • ROS reactive oxygen speies
  • the mixed extract of the forget-me-not and North Lake of the present invention has the activity of inhibiting the production of ROS in the cell, it was confirmed that there is excellent antioxidant efficacy.
  • EOL-1 cells were dispensed into 24 well plates at a concentration of 5 ⁇ 10 5 cells / ml and incubated for 24 hours. The cells were treated with varying concentrations of mixed forget-me-not and Hoshiho lakes (1 or 10 ⁇ g / ml). After 4 hours, PMA (Phorbol myristate acetage) and calcium ionophore (calcium ionophore) A23187 were each treated at a concentration of 50 ng / ml and incubated for 24 hours.
  • PMA Phorbol myristate acetage
  • calcium ionophore calcium ionophore
  • IL-6 Interleukin 6
  • MCP-1 monocyte chemoattractant protein-1
  • TNF-alpha Tumor Necrosis Factor- ⁇
  • the mixed extract of the forget-me-not and North Sea lake of the present invention has the activity of reducing the production of increased cytokines by LPS, it was confirmed that there is excellent anti-inflammatory effect.
  • mice experiments were performed.
  • 4 weeks old male ICR mouse (Coatech Co., Ltd.) was used, and the experiment was performed after a stabilization period of one week.
  • the average weight of the mice was 25 g, fasting from 6 pm the day before the experiment to 9 am on the day of the experiment.
  • mice were administered one hour before gastric ulcer induction, in the case of normal group (A) and gastric ulcer-induced control group (B), water was used instead of the sample, and in the positive control group (C), sucralate (Sigma, USA) Oral administration at a concentration of 100 mg / kg.
  • Experimental group D to F group were orally administered mixed extracts of forget-me-not and Hoshiho at a concentration of 1, 10 or 100 mg / kg, respectively.
  • Sucralate was used by suspending in a 0.25% sodium carboxymethyl cellulose (Samchun Chemicals, Korea) solution, and the mixed extract of forget-me-not and North Sea lake was suspended in water.
  • gastric ulceration was induced by oral administration of 150 mL of hydrochloric acid / ethanol at 0.2 mL per mouse. An hour later, asphyxiated with carbon dioxide and dissected.
  • the stomach of the mouse was incised in the direction of the greater curvature, the inside of the stomach was washed with saline, and soaked in 10% formalin (neutral buffered formalin, Sigma, USA) solution and fixed for 12 hours. After fixing the fixed stomach tissue with paraffin, it was cut to 8 ⁇ m thickness to prepare a longitudinal section of the stomach. After removing paraffin from the sections, H & E staining was performed using hematoxylin and eosin and observed under a microscope. The area of gastric injury was measured using the Isolution lite program. The results are shown in Table 3, FIG. 9 and FIG.
  • the mixed extract of the forget-me-not and North Sea lake of the present invention is similar to the case of the administration of 100 mg / kg sucralate used as a positive control even at a low concentration of 1 mg / kg
  • gastric ulcer protection was observed about 96%.
  • the gastric ulcer induction control group (B) was severe bleeding of the gastric mucosa, damage to the submucosa, but the group administered the mixed extract of the forget-me-not and North Sea lake of the present invention (D In the case of ⁇ F), it was confirmed that bleeding and damage of the gastric mucosa were greatly alleviated.
  • the mixed extract of the forget-me-not and North Sea lake of the present invention was excellent in the protective effect and gastric ulcer inhibiting effect of the gastric mucosa area, it was confirmed that the excellent therapeutic efficacy of gastrointestinal diseases.
  • tablets were prepared by tableting according to a conventional method for producing tablets.
  • the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
  • Vitamin B6 0.5 mg
  • composition ratio of the vitamin and mineral mixture is a composition suitable for a relatively healthy food in a preferred embodiment
  • the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method.
  • the granules may be prepared and used for preparing a health food composition according to a conventional method.
  • the resulting solution is filtered and obtained in a sterilized 2 l container, sealed sterilization and refrigerated and then Used to prepare the healthy beverage composition of the invention.
  • composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
  • Mixed extract of the forget-me-not and North Sea lake according to the present invention is excellent in the protective effect and gastric ulcer suppression effect of the gastric mucosa, it can be usefully used for the prevention or treatment of gastrointestinal diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition contenant un mélange d'extraits de Conyza canadensis et de Bupleurum falcatum comme ingrédients actifs pour la prévention ou le traitement de maladies gastro-intestinales. Le mélange d'extraits de Conyza canadensis et de Bupleurum falcatum présente d'excellents effets dans la protection de la muqueuse gastrique et l'inhibition des ulcères gastriques et est ainsi utile pour la prévention ou le traitement de maladies gastro-intestinales.
PCT/KR2012/002281 2011-04-04 2012-03-28 Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales WO2012138076A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020110030581A KR20110056459A (ko) 2011-04-04 2011-04-04 치주질환의 예방 및 개선용 조성물
KR10-2011-0030581 2011-04-04
KR1020120031495A KR101606773B1 (ko) 2011-04-04 2012-03-28 생약재 혼합 추출물을 포함하는 위장질환의 예방 또는 치료용 조성물
KR10-2012-0031495 2012-03-28

Publications (2)

Publication Number Publication Date
WO2012138076A2 true WO2012138076A2 (fr) 2012-10-11
WO2012138076A3 WO2012138076A3 (fr) 2013-01-10

Family

ID=46969645

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002281 WO2012138076A2 (fr) 2011-04-04 2012-03-28 Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales

Country Status (1)

Country Link
WO (1) WO2012138076A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103405640A (zh) * 2013-08-19 2013-11-27 姜春杰 一种用于晚期妊娠引产术前的清肠颗粒制备方法
RU2637644C1 (ru) * 2016-12-26 2017-12-05 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт лекарственных и ароматических растений" (ФГБНУ ВИЛАР) Лекарственное средство, обладающее гастропротективной (противоязвенной) активностью
CN109010785A (zh) * 2018-11-01 2018-12-18 长江大学 一种治疗慢性胃炎及胃溃疡的中药丸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090180974A1 (en) * 2005-11-02 2009-07-16 Hans-Emanuel Holzgang Agent For Protecting Body Cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090180974A1 (en) * 2005-11-02 2009-07-16 Hans-Emanuel Holzgang Agent For Protecting Body Cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEPORATTI, M. L. ET AL.: 'Comparative Analysis of Medicinal Plants Used in Traditional Medicine in Italy and Tunisia.' JOURNAL OF ETHNOBIOLOGY AND ETHNOMEDICINE. vol. 5, no. 31, 26 October 2009, pages 1 - 8 *
LI, YANG ET AL.: 'In vitro Anti-Helicobacter pylori Action of 30 Chinese Herbal Medicines Used to Treat Ulcer Diseases.' JOURNAL OF ETHNOPHARMACOLOGY vol. 98, no. 3, 26 April 2005, pages 329 - 333 *
MATSUMOTO, T. ET AL.: 'Effect of the antiulcer Polysaccharide Fraction from Bupleurum falcatum L. on the Healing of Gastric Ulcer Induced by Acetic Acid in Rats.' PHYTOTHERAPY RESEARCH vol. 16, no. 1, February 2002, pages 91 - 93 *
XIE, W. D. ET AL.: 'A New C-10 Acetylene and A New Triterpenoid from Conyza canadensis.' ARCHIVES OF PHARMACAL RESEARCH. vol. 30, no. 5, 2007, pages 547 - 551 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103405640A (zh) * 2013-08-19 2013-11-27 姜春杰 一种用于晚期妊娠引产术前的清肠颗粒制备方法
RU2637644C1 (ru) * 2016-12-26 2017-12-05 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт лекарственных и ароматических растений" (ФГБНУ ВИЛАР) Лекарственное средство, обладающее гастропротективной (противоязвенной) активностью
CN109010785A (zh) * 2018-11-01 2018-12-18 长江大学 一种治疗慢性胃炎及胃溃疡的中药丸

Also Published As

Publication number Publication date
WO2012138076A3 (fr) 2013-01-10

Similar Documents

Publication Publication Date Title
KR101099004B1 (ko) 위장질환의 예방 또는 개선용 조성물
WO2015190760A1 (fr) Composition pour la prévention et le traitement de la stéatose hépatique non alcoolique
EP2643007A2 (fr) Composition pharmaceutique comportant un extrait de lonicera japonica pour prévenir et traiter le reflux gastro- sophagien pathologique
WO2015020506A1 (fr) Aliment, boisson ou composition pharmaceutique contenant une oponce de l'est fermentée et procédé de préparation associé
WO2018236011A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'une diminution de la fonction intestinale, comprenant un hydrolysat de pousses de bambou ou des pousses de bambou fermentées en tant que principe actif
KR20140116282A (ko) 발효울금 추출물을 유효성분으로 포함하는 위장질환의 예방 또는 치료용 조성물
WO2012138076A2 (fr) Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales
KR101045368B1 (ko) 베타닌을 유효성분으로 포함하는 위장질환 예방 또는 치료용 조성물
KR100927101B1 (ko) 산겨릅나무 추출물 또는 이로부터 분리된 살리드로사이드를포함하는 위염 및 소화성 궤양의 예방 또는 치료용 조성물
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2017073849A1 (fr) Composition pour la prévention ou le traitement de l'arthrite, contenant un extrait de sargassum serratifolium en tant que substance active
WO2016190566A2 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2018131780A1 (fr) Composition destinée à prévenir ou à traiter la gastrite ou l'ulcère gastroduodénal
KR101606773B1 (ko) 생약재 혼합 추출물을 포함하는 위장질환의 예방 또는 치료용 조성물
WO2014133286A1 (fr) Composition contenant des extraits d'artemisia iwayomogi et de curcuma longa en tant que principes actifs pour la prévention, l'inhibition ou le traitement de maladies se rapportant à l'obésité
WO2018038293A1 (fr) Composition pharmaceutique contenant un extrait de sophora japonica l. en tant que principe actif pour la prévention et le traitement de troubles neurodégénératifs
WO2019245245A1 (fr) Composition pharmaceutique pour la prévention et le traitement d'une lésion hépatique comprenant un extrait de curcuma
KR100506426B1 (ko) 강황 추출물을 함유한 위염, 위궤양 예방 및 치료를 위한조성물
WO2016114621A2 (fr) Composition pour la prévention ou le traitement de maladies métaboliques osseuses comprenant un extrait combiné de schisandra chinesis, d'eucommiae cortex et de lycium chinense comme ingrédient efficace
WO2020004858A1 (fr) Composition pour soulager le diabète ou antioxydante comprenant un extrait de levure et procédé de préparation d'extrait de levure
KR20080094982A (ko) 귤껍질 분말 또는 이의 추출물을 함유하는 위장 질환 예방및 치료용 조성물
WO2024191115A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de maladies gastro-intestinales, comprenant un extrait de cucumis melo l. en tant que principe actif
WO2023033535A1 (fr) Composition comprenant un extrait de marron d'inde
KR102180998B1 (ko) 결명자 추출물을 포함하는 위장질환 예방 및 치료용 조성물
WO2024117801A1 (fr) Composition pour la prévention, le traitement ou l'atténuation d'une maladie inflammatoire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12767415

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12767415

Country of ref document: EP

Kind code of ref document: A2